BOA Biomedical is a Miraki Innovation company focused on infectious disease. Our technology aspires to bring quantum leaps in diagnosis, tracking and treatment.
The world mourns the loss of Dr. Paul Farmer, infectious disease specialist and medical anthropologist. Dr. Farmer championed global health and sought to bring modern medical science to those most in need around the world.
#globalhealth#PaulFarmer
https://t.co/nBcQABHfc5
Nisha Varma, BOA Biomedical COO & @Mirakinnovation Venture Director, discusses BOA's innovative platform technology and how it is designed to detect, diagnose and treat infectious disease resulting from a broad spectrum of pathogens.
@CJPVelis, Founder & Executive Chairman, @Mirakinnovation, discusses how BOA Biomedical is solving the problems related to infectious disease. BOA's technology provides pan-pathogenic countermeasures that will enable disease identification, tracking as well as treatment.
"More than 1.2 million died in 2019 as a direct result of antibiotic-resistant bacterial infections"
BOA is developing technologies to combat future pandemics, biothreats and antibiotic resistant disease that leads to sepsis and death. #sepsisawareness
https://t.co/osdFC3KSxN
BOA Biomedical is excited to announce the appointment of Michael McCurdy, MD, FAAEM, FCCM to the position of Chief Medical Officer. We look forward to Dr. McCurdy’s leadership as BOA continues product development and clinical trials in our fight against infectious disease.
Former President Clinton developed a potentially life-threatening condition known as sepsis. Almost any infection, including COVID-19, can lead to sepsis. BOA’s mission is to identify and stop infections before they cause suffering and loss. #sepsis#Covid_19#MedTech
Today is World Sepsis Day 2021.
1. One in five deaths globally is associated with #sepsis
2. Sepsis is the most preventable cause of death worldwide. It can be prevented by #vaccination, #sanitation, and #Awareness
More information can be found here. https://t.co/SA7ku3XIJo
September is Sepsis Awareness Month! Sepsis affects more than a million Americans each year and kills up to half of them. A new survey published by @SepsisAlliance found that fewer than half of all Americans have ever even heard of the term ‘sepsis.’ #SepsisAwarenessMonth
"As our first in human clinical trial continues, we look forward to continuing to validate GARNET’s safety and documenting the reported clinical benefits received by patients enrolled in the study."-Nisha Varma, COO
#infectiousdisease#MedTech
https://t.co/Fag3YtSU7W
The @lsintelligence Emerging Medtech Summit 2021 featured a compelling talk by @CJPVelis. Chris provided insights into the pandemic and how BOA Biomedical is responding with medtech countermeasures to ongoing, global threats of infectious disease. #MedTech#infectiousdiseases
Nisha Varma, BOA's COO was interviewed by @Medgadget about GARNET™ extracorporeal blood cleansing therapeutic, designed to remove pathogens and their toxic inflammation-triggering debris (which can lead to sepis) directly from a patient's blood. https://t.co/kCDMm3iwnt
Globally, maternal sepsis is estimated at 5.7 million cases each year and responsible for at least 261,000 deaths annually. This is Maternal Sepsis Week. https://t.co/eRSzYeSFUi @SepsisAlliance#sepsis
During a recent Marcus Evans webinar, Nisha Varma, COO BOA Biomedical, discusses the four key factors that have enabled BOA to progress from concept to human clinical trials in less than two years. @Mirakinnovation#infectiousdisease
A recent 60 Minutes report on a DOD study:An extracorporeal filter (FDA approved for emergency use) is attached to a dialysis machine to reduce the level of pathogens in the blood that lead to sepsis. Patient made a full recovery. https://t.co/YwhfE5qnxN #COVID19@wyssinstitute
We're so proud of this news from @BOABiomedical - GARNET™, a product using methods first developed at the Wyss, will begin First in Human clinical trial. https://t.co/gl4y2fwWPJ
BOA Biomedical is excited to announce it will begin its First in Human clinical trial for GARNET™, an extracorporeal blood cleansing therapeutic with the potential to remove over 100 pathogens including SARS-CoV-2. @wyssinstitute@Mirakinnovation https://t.co/fYGZ1jQ3wb